HeraMED (ASX:HMD) - CEO, David Groberman
CEO, David Groberman
Source: HeraMED
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Pregnancy technology company HeraMED (HMD) receives interim results from its paid pilot agreement with Obstetrix Medical Group
  • The interim results have been very positive with an 89 per cent overall positive patient adherence rate achieved
  • Furthermore, 100 per cent of the professional care team indicated HeraCARE is safe and effective and would recommend it to other care teams
  • The second pilot site will be the Obstetrix practice in Atlanta, Georgia, with shipment of the hardware expected on September 15
  • Shares in HeraMED are up 11.4 per cent on the market and are trading at 19.5 cents at 12:30 pm AEST

Pregnancy technology company HeraMED (HMD) has received interim results from its paid pilot agreement with Obstetrix Medical Group.

The companies signed an agreement in mid-May to evaluate the functionality and suitability of the HeraCARE platform.

Upon completion of the pilot agreement, both HeraMED and Obstetrix will determine whether to enter a comprehensive agreement for wider deployment.

HeraCARE is an at-home digital pregnancy monitoring software-as-a-service platform designed to improve prenatal and postnatal care.

It does this by allowing mothers to become engaged in a collaborative process focussed on managing the social, medical and mental aspects of maternity.

Expecting mothers can read articles and blogs with the most recent and accurate information surrounding pregnancy.

The interim results have been very positive with an 89 per cent overall positive patient adherence rate achieved.

Furthermore, 100 per cent of the professional care team indicated HeraCARE is safe and effective and would recommend it to other care teams.

Around 90 per cent of patients answered “definitely” or “yes” to the question “Has HeraCARE contributed to peace of mind during your pregnancy?” while 100 per cent of patients answered “true” to the question “Do you feel supported by your care team and this program?”

Co Founder and CEO David Groberman is pleased with the interim results.

“Our focus throughout the development of the HeraBEAT smart pregnancy monitor and HeraCARE platform was to make our technology easy to use and deliver an improved holistic experience for expectant mothers while ensuring safety, accuracy and the highest level of quality,” Mr Groberman said.

“I am very excited about these interim results as they clearly demonstrate that we have accomplished our primary goals, as evidenced by the decision by Obstetrix to undertake a second paid pilot in Atlanta, Georgia.”

The second pilot site will be the Obstetrix practice in Atlanta, Georgia, with shipment of the hardware expected on September 15.

Shares in HeraMED were up 11.4 per cent on the market and were trading at 19.5 cents at 12:30 pm AEST.

HMD by the numbers
More From The Market Herald

" Resonance Health (ASX:RHT) contracted for third party liver disease study

Resonance Health (ASX:RHT) has been contracted to provide liver-fat quantification services for a clinical study to…

" Cann Group (ASX:CAN) granted GMP licence by TGA

Cann Group (ASX:CAN) receives a GMP licence from the Therapeutic Goods Administration (TGA) to manufacture therapeutic…
1st Group (ASX:1ST) - Managing Director, Klaus Bartosch

" 1st Group (ASX:1ST) shares rise on Visionflex acquisition

Digital health company 1st Group (ASX:1ST) was up as much as 25 per cent on the…
Atomo Diagnostics (ASX:AT1) - Managing Director, John Kelly

" Atomo Diagnostics (ASX:AT1) sees growth in cash receipts as demand for rapid antigen tests soars

Atomo Diagnostics (ASX:AT1) sees growth in cash receipts as demand for rapid antigen tests soars